top of page
News, Events and Updates
Search
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023
ANAVEX®2-73 Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 15, 2023
Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ
Jun 12, 2023
Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jun 6, 2023
ANAVEX Announces New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
Jun 1, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 9, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
May 2, 2023
Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)
May 1, 2023
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Apr 25, 2023
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Apr 10, 2023
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Mar 30, 2023
4
5
6
7
8
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
